Clara Alsinet Armengol
Clara Alsinet Armengol
Wellcome Sanger Institute
E-mail confirmado em sanger.ac.uk
Título
Citado por
Citado por
Ano
Pivotal role of mTOR signaling in hepatocellular carcinoma
A Villanueva, DY Chiang, P Newell, J Peix, S Thung, C Alsinet, V Tovar, ...
Gastroenterology 135 (6), 1972-1983. e11, 2008
7192008
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma
DY Chiang, A Villanueva, Y Hoshida, J Peix, P Newell, B Minguez, ...
Cancer research 68 (16), 6779-6788, 2008
5712008
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes
D Sia, Y Hoshida, A Villanueva, S Roayaie, J Ferrer, B Tabak, J Peix, ...
Gastroenterology 144 (4), 829-840, 2013
3792013
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma
A Villanueva, Y Hoshida, C Battiston, V Tovar, D Sia, C Alsinet, ...
Gastroenterology 140 (5), 1501-1512. e2, 2011
3712011
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice
A Villanueva, C Alsinet, K Yanger, Y Hoshida, Y Zong, S Toffanin, ...
Gastroenterology 143 (6), 1660-1669. e7, 2012
2862012
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage
V Tovar, C Alsinet, A Villanueva, Y Hoshida, DY Chiang, M Solé, S Thung, ...
Journal of hepatology 52 (4), 550-559, 2010
2622010
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
P Newell, S Toffanin, A Villanueva, DY Chiang, B Minguez, L Cabellos, ...
Journal of hepatology 51 (4), 725-733, 2009
2482009
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib
A Lachenmayer, C Alsinet, R Savic, L Cabellos, S Toffanin, Y Hoshida, ...
Clinical cancer research 18 (18), 4997-5007, 2012
2442012
UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma
R Mudbhary, Y Hoshida, Y Chernyavskaya, V Jacob, A Villanueva, MI Fiel, ...
Cancer Cell 25 (2), 196-209, 2014
2352014
Predicting the mutations generated by repair of Cas9-induced double-strand breaks
F Allen, L Crepaldi, C Alsinet, AJ Strong, V Kleshchevnikov, P De Angeli, ...
Nature biotechnology 37 (1), 64, 2019
2342019
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a
S Toffanin, Y Hoshida, A Lachenmayer, A Villanueva, L Cabellos, ...
Gastroenterology 140 (5), 1618-1628. e16, 2011
2312011
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib
A Lachenmayer, S Toffanin, L Cabellos, C Alsinet, Y Hoshida, ...
Journal of hepatology 56 (6), 1343-1350, 2012
1832012
New strategies in hepatocellular carcinoma: genomic prognostic markers
A Villanueva, Y Hoshida, S Toffanin, A Lachenmayer, C Alsinet, R Savic, ...
Clinical Cancer Research 16 (19), 4688-4694, 2010
1362010
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
V Tovar, H Cornella, A Moeini, S Vidal, Y Hoshida, D Sia, J Peix, ...
Gut 66 (3), 530-540, 2017
1212017
Molecular approaches to treatment of hepatocellular carcinoma
A Lachenmayer, C Alsinet, CY Chang, JM Llovet
Digestive and Liver Disease 42, S264-S272, 2010
1052010
Unique genomic profile of fibrolamellar hepatocellular carcinoma
H Cornella, C Alsinet, S Sayols, Z Zhang, K Hao, L Cabellos, Y Hoshida, ...
Gastroenterology 148 (4), 806-818. e10, 2015
982015
VEGF signaling in cancer treatment
D Sia, C Alsinet, P Newell, A Villanueva
Current pharmaceutical design 20 (17), 2834-2842, 2014
872014
IGF2 is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and is an Actionable Oncogene Product in Experimental Models
I Martinez-Quetglas, R Pinyol, D Dauch, S Torrecilla, V Tovar, A Moeini, ...
Gastroenterology 151 (6), 1192-1205, 2016
712016
Genomic determinants of protein abundance variation in colorectal cancer cells
TI Roumeliotis, SP Williams, E Gonçalves, C Alsinet, ...
Cell reports 20 (9), 2201-2214, 2017
692017
DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
L Cornell, JM Munck, C Alsinet, A Villanueva, L Ogle, CE Willoughby, ...
Clinical Cancer Research 21 (4), 925-933, 2015
682015
O sistema não pode executar a operação agora. Tente novamente mais tarde.
Artigos 1–20